Retatrutide vs Tirzepatide: Which Weight-Loss Shot Wins—and Which One You Can Actually Get

Retatrutide trimmed up to 24 % of body weight in a 48-week phase 2 study, but it remains an unapproved, research-only drug and is illegal to sell for personal use in the United States. Tirzepatide—already FDA-approved as Zepbound for obesity and Mounjaro for diabetes—achieves up to 23 % loss at 72 weeks and can be prescribed today, including lower-cost compounded formulations. Until retatrutide finishes phase 3 trials and gains approval, tirzepatide is the practical, legal choice for most adults seeking a powerful GLP-1–based weight-loss injection.

• Retatrutide is a “triple agonist” (GIP + GLP-1 + glucagon) still in phase 3 testing; it has no FDA approval or lawful retail market. [pubmed.ncbi.nlm.nih.gov]
• Tirzepatide is a dual GIP + GLP-1 agonist approved as Zepbound for chronic weight management on November 8, 2023.  [fda.gov]
• Average weight loss was 24 % with high-dose retatrutide at 48 weeks versus 22 % with 15 mg tirzepatide at 72 weeks—both among the best ever recorded.  [pubmed.ncbi.nlm.nih.gov]
• The FDA has issued multiple warning letters stating that compounded retatrutide is illegal because the substance is not on the 503A or 503B bulks lists.  [fda.gov]
• Compounded tirzepatide remains an option while commercial supply fluctuates, and most Rx.com patients pay about $149 per month using our tirzepatide online provider.
• Choose tirzepatide now if you need treatment in 2026; consider retatrutide in a few years once safety and price are clearer.

What Retatrutide and Tirzepatide Are

Retatrutide is an investigational, once-weekly injectable that activates three metabolic receptors—GIP, GLP-1 and glucagon—while tirzepatide activates two (GIP + GLP-1) and is already FDA-approved. Retatrutide’s triple-target design aims to enhance satiety, slow gastric emptying and increase energy expenditure. Tirzepatide, sold as Mounjaro for type 2 diabetes and as Zepbound for obesity, combines GIP and GLP-1 signaling to suppress appetite and improve insulin sensitivity.

Definition (60 words): Retatrutide vs tirzepatide refers to comparing two injectable hormone-based treatments: retatrutide, a research-stage GIP/GLP-1/glucagon agonist not yet approved, and tirzepatide, an FDA-approved GIP/GLP-1 agonist marketed for diabetes and weight loss. Key differences include regulatory status, receptor targets, published efficacy, side-effect data, and current availability for patients.

How the Two Drugs Promote Weight Loss

Both medicines mimic gut hormones that blunt hunger, but retatrutide also stimulates glucagon receptors, potentially increasing calorie burn. Here’s how each pathway helps:

GIP activation: Improves insulin secretion after meals, reducing fat storage.

GLP-1 activation: Slows stomach emptying, lowers appetite, and sends fullness signals to the brain—similar to Ozempic.

Glucagon activation (retatrutide only): May raise resting energy expenditure and mobilize liver glycogen, amplifying fat-burning—one reason researchers suspect the drug hits >20 % loss sooner.

Which Delivers Greater Weight Loss in Trials

Retatrutide edges out tirzepatide in early head-to-head data, but longer follow-up favors tirzepatide’s durable results.

The headline: at roughly one year, both drugs produce transformational weight reduction; statistical differences are small and trial designs differ.  [pubmed.ncbi.nlm.nih.gov]

Side-Effect and Safety Differences

Gastrointestinal (GI) issues dominate both profiles, but retatrutide’s higher receptor activity produced slightly more nausea and diarrhea in phase 2.

Common reactions: nausea (48 % retatrutide vs 44 % tirzepatide), constipation, vomiting and fatigue. Serious adverse events were infrequent (<4 %) in each program.  [pubmed.ncbi.nlm.nih.gov]

Thyroid tumors: Both agents carry a class warning for medullary thyroid carcinoma based on rodent data.

Blood pressure and heart rate: Each lowered systolic pressure by ~6 mm Hg; heart-rate increases averaged 2–3 beats per minute—clinically mild but worth monitoring.

Why You Can’t (Legally) Buy Retatrutide Yet

Retatrutide is under an Investigational New Drug (IND) application; selling it for personal use violates federal law. The FDA has issued at least five warning letters in the past year to clinics and online “research peptide” vendors offering compounded retatrutide.  [fda.gov]

Not on the 503A or 503B bulks lists: Because retatrutide is neither an approved component nor on the FDA’s bulks lists, pharmacies lose their compounding exemptions—making any U.S. sale misbranded and “adulterated” under the FD&C Act.

Expanded-access loophole: Only a physician can request single-patient compassionate use directly from Lilly and the FDA, a months-long process reserved for life-threatening cases—not general weight management.  [fda.gov]

Ready to Start Losing Weight Safely?

How to Start Tirzepatide Today—Including Compounded Options

Tirzepatide is available through three pathways: commercial pens (Zepbound or Mounjaro), pharmacy-compounded vials, or clinical trials.

Commercial supply: Insurance approval can be slow, and WAC (wholesale acquisition cost) sits near $1,089 per 4-week pack.

Compounded tirzepatide: During recent shortages, 503A pharmacies have lawfully compounded tirzepatide using finished-drug repackaging, not bulk powder. The FDA continues to evaluate this practice but has not taken broad enforcement while patients lack access. ([fda.gov](https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize?utm_source=openai))

Use Rx.com’s compounded-tirzepatide guide to understand vial dosing and safety, or explore cheapest tirzepatide online for savings tips.

Cost Breakdown: Brand vs Compounded Tirzepatide

Compounded vials typically cost one-third of the brand-name pens.

Use Rx.com to compare prices—most patients pay around $397 or less with a free discount card.